Zelu Zheng , Xiaohan Wang , Baohong Mi , Jun Zhou , Yan Yan , Shuwen Li , Yuxin Luo , Kaiqiang Tang , Yawei Dong , Rui Quan , Jiaming Lin , Jiawen Zhang , Jiachun Liu , Yuhang Shi , Rongtian Wang , Yanqiong Zhang , Na Lin , Xisheng Weng , Weiheng Chen
{"title":"Tenghuang Jiangu tablet in knee osteoarthritis therapy: A prospective multicenter registry study in China","authors":"Zelu Zheng , Xiaohan Wang , Baohong Mi , Jun Zhou , Yan Yan , Shuwen Li , Yuxin Luo , Kaiqiang Tang , Yawei Dong , Rui Quan , Jiaming Lin , Jiawen Zhang , Jiachun Liu , Yuhang Shi , Rongtian Wang , Yanqiong Zhang , Na Lin , Xisheng Weng , Weiheng Chen","doi":"10.1016/j.jep.2025.119525","DOIUrl":null,"url":null,"abstract":"<div><h3>Ethnopharmacological relevance</h3><div>Chinese patent medicine Tenghuang Jiangu tablet (THJGT) is frequently used to treat knee osteoarthritis (KOA).</div></div><div><h3>Aim</h3><div>This prospective multicenter registry study investigated the effectiveness and safety of THJGT in treating KOA.</div></div><div><h3>Materials and methods</h3><div>Patients with KOA aged 50–75 years were preferentially treated with THJGT, other nonsurgical conventional treatments (CTs), or both. The treatment duration was 8 weeks, with follow-ups at weeks 4 and 8. The visual analog scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were the efficacy assessments. Adverse events and drug reactions were evaluated to assess the safety of THJGT. Propensity score matching (PSM) was used for the subgroup analysis.</div></div><div><h3>Results</h3><div>From September 2019 to January 2021, a total of 2995 participants were included, with 1471 in THJGT group, 490 in CT group and 1034 in THJGT + CT group. After treatment, the VAS and WOMAC scores in the three groups improved significantly (<em>P</em> < 0.001). At week 8, the VAS scores in the THJGT group significantly improved, were lower than those in the CT group (<em>P</em> < 0.01), and were comparable to those in the THJGT + CT group (<em>P</em> = 0.623). The WOMAC scores significantly improved (<em>P</em> < 0.001), with no differences between groups (P > 0.05). The WOMAC pain and stiffness scores were better in the THJGT + CT than in the THJGT and CT groups. PSM revealed that the WOMAC pain and stiffness scores were significantly lower in the THJGT than in the nonsteroidal anti-inflammatory drugs (NSAID) group (<em>P</em> < 0.01 and 0.001). Adverse events were higher in the CT and THJGT + CT groups (<em>P</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>THJGT is effective and safe for treating KOA, particularly in improving stiffness symptoms.</div></div>","PeriodicalId":15761,"journal":{"name":"Journal of ethnopharmacology","volume":"345 ","pages":"Article 119525"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of ethnopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378874125002090","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Tenghuang Jiangu tablet in knee osteoarthritis therapy: A prospective multicenter registry study in China
Ethnopharmacological relevance
Chinese patent medicine Tenghuang Jiangu tablet (THJGT) is frequently used to treat knee osteoarthritis (KOA).
Aim
This prospective multicenter registry study investigated the effectiveness and safety of THJGT in treating KOA.
Materials and methods
Patients with KOA aged 50–75 years were preferentially treated with THJGT, other nonsurgical conventional treatments (CTs), or both. The treatment duration was 8 weeks, with follow-ups at weeks 4 and 8. The visual analog scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were the efficacy assessments. Adverse events and drug reactions were evaluated to assess the safety of THJGT. Propensity score matching (PSM) was used for the subgroup analysis.
Results
From September 2019 to January 2021, a total of 2995 participants were included, with 1471 in THJGT group, 490 in CT group and 1034 in THJGT + CT group. After treatment, the VAS and WOMAC scores in the three groups improved significantly (P < 0.001). At week 8, the VAS scores in the THJGT group significantly improved, were lower than those in the CT group (P < 0.01), and were comparable to those in the THJGT + CT group (P = 0.623). The WOMAC scores significantly improved (P < 0.001), with no differences between groups (P > 0.05). The WOMAC pain and stiffness scores were better in the THJGT + CT than in the THJGT and CT groups. PSM revealed that the WOMAC pain and stiffness scores were significantly lower in the THJGT than in the nonsteroidal anti-inflammatory drugs (NSAID) group (P < 0.01 and 0.001). Adverse events were higher in the CT and THJGT + CT groups (P < 0.001).
Conclusion
THJGT is effective and safe for treating KOA, particularly in improving stiffness symptoms.
期刊介绍：
The Journal of Ethnopharmacology is dedicated to the exchange of information and understandings about people''s use of plants, fungi, animals, microorganisms and minerals and their biological and pharmacological effects based on the principles established through international conventions. Early people confronted with illness and disease, discovered a wealth of useful therapeutic agents in the plant and animal kingdoms. The empirical knowledge of these medicinal substances and their toxic potential was passed on by oral tradition and sometimes recorded in herbals and other texts on materia medica. Many valuable drugs of today (e.g., atropine, ephedrine, tubocurarine, digoxin, reserpine) came into use through the study of indigenous remedies. Chemists continue to use plant-derived drugs (e.g., morphine, taxol, physostigmine, quinidine, emetine) as prototypes in their attempts to develop more effective and less toxic medicinals.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
